Embryo Screening: Reshaping Reproduction

The silent, desperate hope that flickered on an ultrasound monitor after two devastating miscarriages felt less like a medical miracle and more like a quiet rebellion against fate.

For months, I carried that pregnancy under a self-imposed siege, convinced that every shadow held a threat, every ache a premonition.

When my son finally arrived, after a fraught induction and a last-minute scramble of doctors, he was a perfect, tiny bundle, his hat askew, nestled against his father’s chest.

In that emptied delivery room, the world beyond us seemed to vanish.

Here was my family, a testament to resilience, to chance, and to a journey that felt utterly beyond my control.

But what if, in the not-too-distant future, such beginnings are no longer seen as a roll of the dice, but as a meticulously curated outcome?

This is the audacious vision of Silicon Valley’s latest frontier: genomic screening for human embryos, spearheaded by companies like Orchid.

They promise to transform the deeply personal act of reproduction into an exercise in data-driven optimization, challenging our very understanding of what it means to bring a child into the world.

Noor Siddiqui, the 31-year-old founder and CEO of Orchid, embodies this new paradigm.

For her, my son’s birth story—a mix of anxiety, medical intervention, and sheer luck—is precisely the kind of “rolling the dice” she aims to eliminate.

Siddiqui, who has yet to have children, has already frozen more than a dozen embryos, which have been biopsied, their DNA amplified, sequenced, and scored.

Not just for obvious chromosomal abnormalities, which constitute the bulk of current IVF genetic screening (PGT-A), but for cancer, autism, diabetes, birth defects, and hundreds of other diseases.

This, she argues, is preventive medicine, a way for parents to “mitigate a massive amount of risk that was previously left to chance.”

Her conviction is deeply personal.

Siddiqui’s mother lives with a genetic mutation that has slowly stolen her sight.

Armed with a Stanford background in computer science and artificial intelligence, Siddiqui saw a path to merge computational power with genetics, a revelation that became Orchid.

Since its 2019 founding, Orchid has evaluated thousands of embryos, at an out-of-pocket cost of $2,500 per embryo, often for couples screening five or more.

For these early adopters, many of whom are Silicon Valley’s data-savvy elite, the prospect of a detailed embryo report, charting risks and predispositions, is not just appealing; it’s essential.

Take Jeff, a startup founder whose wife endured two miscarriages.

Orchid offered a potential solution, screening their embryos not just for chromosomal issues but also for 1,200 monogenic conditions and a dozen polygenic conditions, including Alzheimer’s, which runs in his wife’s family.

The couple spent upwards of $25,000 on Orchid’s services, in addition to IVF costs, and welcomed a healthy baby last year.

Jeff, now an investor in Orchid, articulates the prevailing sentiment among proponents: “Everyone tries to provide a better life for their kids, wants to send their kids to the best school.

Why would you not want to give your child the highest probability of health success?”

He goes further, advocating for federal support to “eradicate disease” and “improve our gene pools.”

Yet, as Siddiqui walks the Chicago lakefront, her frustration with clinical caution palpable, she’s not just battling skepticism; she’s navigating a minefield of ethical quandaries.

Her now-polarizing catchphrase, “sex is for fun, and embryo screening is for babies,” proudly echoed by some fertility specialists, sends shivers down the spines of ethicists who foresee a Huxleian future of designer babies.

The challenges are manifold.

While screening for clear-cut monogenic conditions like cri du chat syndrome is one thing, the value of polygenic risk scores—which assess predisposition to complex diseases like hypertension or coronary artery disease—is fiercely debated.

These conditions are not solely genetic; environment and lifestyle play significant roles.

A lower risk score doesn’t guarantee immunity, nor does a higher score condemn.

As statistical geneticist Sasha Gusev points out, “There’s no such thing as half cancer,” highlighting the danger of fostering false hope or certainty.

Moreover, the line between preventing disease and enhancing traits quickly blurs.

While Orchid claims to focus only on disease, competitors like Nucleus Genomics, founded by another Thiel Fellow, Kian Sadeghi, openly embrace “genetic optimization” for traits like height, IQ, hair color, and even male-pattern baldness.

This consumer-driven approach, where an embryo report feels less like a medical assessment and more like a product catalog, raises uncomfortable questions about equity and societal values.

Who gets to define “best”?

And what happens to those who don’t fit the optimized mold?

The cost alone—tens of thousands of dollars beyond standard IVF—ensures that this technology remains a luxury, deepening existing health disparities.

It encourages a kind of reproductive arms race among those with economic means, where the goal is not just a healthy child, but the “best” child, optimized for a lifetime of success and minimal medical burden.

Even nature, in its seemingly haphazard way, has its own form of optimization.

The narrator reflects on her miscarriages, painful as they were, acknowledging they were likely “safeguarding me,” a natural rejection of embryos with chromosomal abnormalities.

This underscores a profound tension: the Silicon Valley drive to control and de-risk, pitted against the inherent intelligence and unpredictability of biological life.

Companies like Orchid are still too young to have a population-level impact, but researchers like Patrick Turley are already envisioning a future where cost-focused healthcare systems might embrace embryo screening to reduce long-term medical expenditures.

The promise of reduced suffering and lower lifetime costs is undeniably attractive.

But in this quest for a “highest probability of health success,” are we losing something vital?

Are we transforming children from gifts, however imperfect, into products to be designed, optimized, and ultimately, judged by their genetic scores?

My son, the one whose chaotic arrival defied every expectation, is now six.

Was he the “best” baby?

Is he the “best” six-year-old?

The question feels absurd, just as asking if I am the “best” mom would be.

All I know, with a certainty deeper than any algorithm, is that he is mine.

And in that simple truth, perhaps, lies a wisdom that no amount of genomic data can ever fully capture.